Physician

Abdeen Rihan Farah Musa, MBBS

According to 2025 Medicare claims, Abdeen Musa, MBBS (NPI: 1568637627) practices nephrology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is BAYCARE MEDICAL GROUP, INC. (NPI: 1043269871; TIN: 593140335) and primary practice location at 33705-1300. Musa is affiliated with the TC2, LLC (ACO ID: A3365), Health Leaders Network of Mississippi LLC (ACO ID: A5148), and Pearl Network, LLC (ACO ID: D0243), participating under both the MSSP and REACH models.

Musa's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 411 traditional Medicare patients, billed 1,350 HCPCS/CPT codes, and received $123,666 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 629 prescription claims across 166 beneficiaries totaling $15,848 in drug costs, led by Sevelamer Carbonate (Sevelamer Carbonate). DME data shows 11 claims. Open Payments data shows 25 records totaling $696. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $129,461 to $123,666. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $24,666 and ending at $15,848. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $865 to $1,793.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	439	1,753	$129,461
2016	580	22,744	$631,937
2017	575	4,415	$209,308
2018	531	1,851	$133,519
2019	498	1,352	$89,678
2020	178	324	$26,516
2021	N/R	N/R	N/R
2022	250	956	$125,539
2023	273	797	$90,274
2024	411	1,350	$123,666

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	66	228	$24,666
2016	24	409	$134,605
2017	80	300	$39,613
2018	138	364	$27,134
2019	93	160	$13,215
2020	182	815	$49,943
2021	289	1,843	$107,343
2022	321	2,505	$227,606
2023	269	2,139	$92,567
2024	166	629	$15,848

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	60	$2,124
2019	N/R	36	$1,708
2020	N/R	30	$984
2021	N/R	24	$811
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	11	$207

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	153	164	$142
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	62	62	$128
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	148	325	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	77	101	$85
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	178	385	$65

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Sevelamer Carbonate	Sevelamer Carbonate	14	510	$891
Calcium Acetate	Calcium Acetate	19	570	$754
Nifedipine Er	Nifedipine	24	992	$596
Doxazosin Mesylate	Doxazosin Mesylate	83	3,720	$559
Bumetanide	Bumetanide	11	600	$460

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$207

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	25	$696	Ardelyx, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdeen Rihan Farah Musa, MBBS?

Tedicare shows public-source Medicare data for Abdeen Rihan Farah Musa, MBBS (NPI 1568637627), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdeen Rihan Farah Musa, MBBS have ACO affiliation data?

Abdeen Rihan Farah Musa, MBBS is shown with ACO affiliation data for TC2, LLC (MSSP, ACO ID A3365), Health Leaders Network of Mississippi LLC (MSSP, ACO ID A5148), and Pearl Network, LLC (REACH, ACO ID D0243).

What billing organization is linked to Abdeen Rihan Farah Musa, MBBS?

Abdeen Rihan Farah Musa, MBBS is linked to BAYCARE MEDICAL GROUP, INC. (billing NPI 1043269871) in the available physician profile data.

Does Abdeen Rihan Farah Musa, MBBS have Open Payments data?

Abdeen Rihan Farah Musa, MBBS has 25 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.